Ginkgo Bioworks Holdings, Inc.
DNAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Ginkgo Bioworks Holdings, Inc. (DNA) is listed under Biotechnology. At a $609.5M market cap, Ginkgo Bioworks Holdings, Inc. ranks as a small-cap company within healthcare. It operates through the Cell Engineering and Biosecurity segments.
Market Cap
$609.5M
Beta
1.78
P/E (TTM)
—
P/E (Fwd)
-2.91
EPS (TTM)
$-5.38
EPS (Fwd)
$-3.21
ROE
-56.0%
ROA
-16.2%
Cash
$373.5M
Total Debt
$410.7M
Free CF
-$77.9M
52W Change
23.4%
Annual Financials
Cash vs Debt
The company holds $373.5M in cash, though total debt stands at $410.7M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow is running at -$77.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -56.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $477.7M (2022) to $170.2M (2025), a 64% decline worth watching.
With a beta above 1.5, DNA tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing DNA.